CTFH

China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)’s FHND1002 granules in the patient-centered rare disease drug development pilot program, known as the Care Plan. The official announcement is expected within the coming week. FHND1002: Focusing on Patient Experience…